MDxHealth Announces Agreement with SouthGenetics
OREANDA-NEWS. MDxHealth SA (Euronext: MDXH.BR) a multinational healthcare company that provides actionable epigenetic information to personalize the diagnosis and treatment of urologic cancers, today announced that it has signed a distribution agreement for their SelectMDx(TM) for Prostate Cancer assay in select countries in Central and South America with SouthGenetics Inc.
Under the terms of the agreement SouthGenetics, a biotechnology distribution company based in Montevideo, Uruguay, will have the rights to distribute SelectMDx assay within the following countries: Argentina, Bolivia, Chili, Columbia, Ecuador, Mexico, Peru, Dominican Republic, Panama, Paraguay, Uruguay, and Venezuela.
"MDxHealth is pleased to have this opportunity to provide SelectMDx testing for patients throughout Latin America through this collaborative agreement with SouthGenetics," stated Dr. Jan Groen, CEO of MDxHealth. "Helping to improve both the quality of care and outcomes for those suspected of harboring prostate cancer throughout Latin America."
Of the nearly 2 million prostate biopsies performed each year, less than a third find cancer. Most of these men could have avoided a painful and invasive prostate biopsy procedure, with its associated complications and costs. SelectMDx for Prostate Cancer is a proprietary urine-based, molecular diagnostic test that offers a non-invasive 'liquid biopsy' method to assess a man's risk for prostate cancer. SelectMDx helps identify men at increased risk of harbouring aggressive, potentially lethal, prostate cancer who may benefit most from a prostate biopsy and earlier detection. The test delivers a negative predictive value (NPV) of 98% for clinically significant disease, helping to reduce unnecessary MRI procedures and invasive prostate biopsies by approximately 50%, thereby reducing healthcare costs.
SouthGenetics is a biotechnology distribution company with presence in major Latin American countries including; Argentina, Colombia, Chile, Dominican Rep, Ecuador, Mexico, Panama, Paraguay, Peru and Venezuela. The company's mission is to provide patients and doctors access to the highest quality emerging diagnostics tools available. Through strategic partnerships it provides high quality diagnostic services in many clinical areas, such us oncology, gynecology and urology.
MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary gene methylation (epigenetic) and other molecular technologies and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy.